Fenfluramine (Fintepla®) for Lennox-Gastaut Syndrome . HTA ID: 23051

Assessment Status Rapid Review Complete
HTA ID 23051
Drug Fenfluramine
Brand Fintepla®
Indication Fenfluramine (Fintepla®) is indicated for patients (two years of age and older) with Lennox-Gastaut Syndrome as an add-on therapy to other anti-epileptic medicines.
Assessment Process
Rapid review commissioned 09/08/2023
Rapid review completed 14/09/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine for this indication compared with the current standard of care.